A simple view on lung cancer biology: The EGFR pathway;Un regard simple sur la biologie du cancer bronchique: EGFR

Revue des Maladies Respiratoires

Volumn 28, Issue 4, 2011, Pages 565-577

  Ruppert, A M ^a   Wislez, M ^a,b   Poulot, V ^a,b   Lacave, R ^a,b   Antoine, M ^a,b   Cadranel, J ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Biomarker; EGFR; Erlotinib; Gefitinib; Predictive; Prognosis; Tyrosine kinase inhibitor; Tyrosine kinase receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ARTICLE; EXON; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; PROGNOSIS; TREATMENT RESPONSE;

EID: 79959550150     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.03.005     Document Type: Review

References (37)

1. EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) [Homo sapiens]-Gene Result [Internet]. OMIM website. 2010 Jun 10 [cité 2010 Jun 17]; Available from: http://www.ncbi.nlm.nih.gov/sites/entrez?dbCombining double low linegene&cmdCombining double low lineretrieve&doptCombining double low linefull-report&list-uidsCombining double low line1956.
2. J.L. Reiter D.W. Threadgill G.D. Eley, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms Genomics 71 2001 1 20 (Pubitemid 32097198)
3. M.A. Lemmon J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
4. Human Protein Atlas [Internet]. [cité 2010 Jul 15]; Available from: http://www.proteinatlas.org/tissue-profile.php?antibody-idCombining double low line35&g-noCombining double low lineENSG00000146648#normal.
5. D.W. Threadgill A.A. Dlugosz L.A. Hansen, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype Science 269 1995 230 234
6. M. Sibilia E.F. Wagner Strain-dependent epithelial defects in mice lacking the EGF receptor Science 269 1995 234 238
7. F. Cappuzzo T. Ciuleanu L. Stelmakh, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
8. T.S. Mok Y. Wu S. Thongprasert, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
9. M. Maemondo A. Inoue K. Kobayashi, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
10. J. Albanell F. Rojo S. Averbuch, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 2002 110 124 (Pubitemid 34032602)
11. X. Zhang J. Gureasko K. Shen, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149 (Pubitemid 43866200)
12. M. Ono M. Kuwano Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs Clin Cancer Res 12 2006 7242 7251 (Pubitemid 46095395)
13. Y. Sekido K.M. Fong J.D. Minna Progress in understanding the molecular pathogenesis of human lung cancer Biochim Biophys Acta 1378 1998 F21 59
14. B. Brandt S. Meyer-Staeckling H. Schmidt, et al. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response Clin Cancer Res 12 2006 7252 7260 (Pubitemid 46095396)
15. T.J. Lynch D.W. Bell R. Sordella, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
16. I. Okamoto L.C. Kenyon D.R. Emlet, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer Cancer Sci 94 2003 50 56 (Pubitemid 36575858)
17. W. Pao V. Miller M. Zakowski, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311 (Pubitemid 39209661)
18. H. Ji D. Li L. Chen, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell 9 2006 485 495 (Pubitemid 43832191)
19. K. Ohashi K. Rai Y. Fujiwara, et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter Cancer Sci 99 2008 1747 1753
20. H. Nakamura N. Kawasaki M. Taguchi, et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis Thorax 61 2006 140 145 (Pubitemid 43235431)
21. F.R. Hirsch M. Varella-Garcia J. McCoy, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 23 2005 6838 6845
22. T. Mitsudomi Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824 (Pubitemid 350002184)
23. F.A. Shepherd J. Rodrigues Pereira T. Ciuleanu, et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
24. D.W. Bell T.J. Lynch S.M. Haserlat, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 2005 8081 8092 (Pubitemid 46657411)
25. European Medicines Agency-Human medicines-Iressa [Internet]. [cité 2010 Jul 20]; Available from: http://www.ema.europa.eu/ema/index.jsp? curlCombining double low linepages/medicines/human/medicines/001016/human-med- 000857.jsp&murlCombining double low linemenus/medicines/medicines. jsp&midCombining double low lineWC0b01ac058001d124.
26. J. Wu S. Wu C. Yang, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response Clin Cancer Res 14 2008 4877 4882
27. A.F. Gazdar Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 2009 S24 31
28. D. Li L. Ambrogio T. Shimamura, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
29. J.A. Engelman K. Zejnullahu T. Mitsudomi, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
30. T. Mitsudomi S. Morita Y. Yatabe, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
31. M. Brevet M. Arcila M. Ladanyi Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR J Mol Diagn 12 2010 169 176
32. C. He M. Liu C. Zhou, et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer Int J Cancer 125 2009 2393 2399
33. A. Inoue K. Kobayashi K. Usui, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
34. N. Thatcher A. Chang P. Parikh, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
35. S.V. Sharma D.W. Bell J. Settleman, et al. Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
36. T. Mitsudomi Y. Yatabe Epidermal growth factor receptor in relation to tumor development: E.G.F.R. gene cancer FEBS J 277 2010 301 308
37. J. Cadranel G. Zalcman L. Sequist Genetic profiling and EGFR-directed therapy: evidence and clinical implications Eur Respir J 37 2011 183 193